<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061906</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-0239</org_study_id>
    <nct_id>NCT00061906</nct_id>
  </id_info>
  <brief_title>Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer</brief_title>
  <official_title>Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the&#xD;
      tumor and by blocking the enzymes necessary for tumor cell growth.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have&#xD;
      progressive metastatic differentiated thyroid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of celecoxib, in terms of progression-free survival, in patients&#xD;
           with progressive metastatic differentiated thyroid carcinoma.&#xD;
&#xD;
        -  Correlate cyclooxygenase (COX)-2 protein expression in tumor biopsies by&#xD;
           immunohistochemistry with clinical response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: Patients receive oral celecoxib twice daily beginning on day 1. Treatment continues&#xD;
      for 1 year in the absence of disease progression or unacceptable toxicity. Patients who&#xD;
      achieve a complete response (CR) receive 3 additional months of therapy beyond documentation&#xD;
      of CR.&#xD;
&#xD;
      Patients are followed at 4-8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within approximately&#xD;
      6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Examine efficacy of celecoxib in patients with progressive metastatic differentiated thyroid carcinoma by assessing progression free survival.</measure>
    <time_frame>up to 12 months following treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantifying gene expression and protein levels of angiogenic markers[vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and tumor necrosis factor (TNF)-α] in peripheral blood mononuclear cells (PBMCs) from pre-,during-</measure>
    <time_frame>pre-study, every eight weeks and off study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantifying gene expression and protein levels of cytokines [interleukin (IL)-10, IL-12, IL-6 and interferon (IFN)-γ] in peripheral blood mononuclear cells from pre-,during-, and post-treatment blood samples.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate cyclooxygenase (COX)-2 protein expression by immunohistochemistry in tumor biopsies to correlate with clinical response.</measure>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.</description>
    <other_name>Celebrex</other_name>
    <other_name>Cobix</other_name>
    <other_name>Celcoxx</other_name>
    <other_name>Celexib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed thyroid carcinoma, including 1 of the following subtypes:&#xD;
&#xD;
               -  Papillary&#xD;
&#xD;
               -  Follicular&#xD;
&#xD;
               -  Hurthle cell&#xD;
&#xD;
               -  Insular&#xD;
&#xD;
          -  Assessable disease, defined by at least 1 of the following:&#xD;
&#xD;
               -  Metastatic (including neck lymph nodes) measurable disease&#xD;
&#xD;
                    -  At least 20 mm by conventional techniques or at least 10 mm by spiral CT&#xD;
                       scan&#xD;
&#xD;
                    -  The following are not considered measurable disease:&#xD;
&#xD;
                         -  Leptomeningeal disease&#xD;
&#xD;
                         -  Ascites&#xD;
&#xD;
                         -  Pleural/pericardial effusion&#xD;
&#xD;
                         -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                         -  Abdominal masses that are not confirmed and followed by imaging&#xD;
                            techniques&#xD;
&#xD;
                         -  Cystic lesions&#xD;
&#xD;
                         -  Tumor lesions within a previously irradiated area&#xD;
&#xD;
               -  Elevated serum thyroglobulin levels indicating the presence of metastatic disease&#xD;
&#xD;
                    -  Must have negative thyroglobulin antibodies&#xD;
&#xD;
          -  Must have progressive disease within the past year, defined by at least 1 of the&#xD;
             following:&#xD;
&#xD;
               -  At least 20% increase in serum thyroglobulin levels&#xD;
&#xD;
               -  At least 20% increase in the sum of the longest diameter of measurable lesions&#xD;
&#xD;
               -  Appearance of at least 1 new lesion&#xD;
&#xD;
          -  Failed or ineligible for standard therapy with iodine I 131 and/or surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 1 year&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No prior symptomatic or complicated peptic ulcer disease by endoscopy within the past&#xD;
             6 months, defined by any of the following conditions:&#xD;
&#xD;
               -  Active gastric or duodenal ulcer&#xD;
&#xD;
               -  Gastric or duodenal perforation&#xD;
&#xD;
               -  Upper gastrointestinal bleeding&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No prior allergic reaction to celecoxib or sulfonamides&#xD;
&#xD;
          -  No prior urticaria, asthma, or allergic reaction to aspirin or other nonsteroidal&#xD;
             anti-inflammatory agents&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled concurrent illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 1 month since prior systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 months since prior external beam radiotherapy (unless an indicator lesion&#xD;
             is outside the radiation field)&#xD;
&#xD;
          -  More than 6 months since prior iodine I 131 therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 1 month since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior conventional doses of celecoxib or rofecoxib for&#xD;
             osteoarthritis, rheumatoid arthritis, or dysmenorrhea&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent chronic (more than 1 week of therapy) fluconazole therapy&#xD;
&#xD;
          -  Concurrent oral or IV bisphosphonates for bony metastases are allowed&#xD;
&#xD;
          -  Concurrent low-dose aspirin (no greater than 325 mg/day) for cardiovascular disease is&#xD;
             allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha H. Shah, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comrehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <results_reference>
    <citation>Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jun;91(6):2201-4. Epub 2006 Mar 7.</citation>
    <PMID>16522694</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Manisha Shah</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>insular thyroid cancer</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <keyword>stage II follicular thyroid cancer</keyword>
  <keyword>stage II papillary thyroid cancer</keyword>
  <keyword>stage IV follicular thyroid cancer</keyword>
  <keyword>stage IV papillary thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

